Oct 17, 2016 11:23 AM IST IST | Source: PTI

Granules Hyderabad plant successfully closes USFDA inspection

"The company's Gagillapur facility located in Hyderabad, Telangana... has successfully completed US FDA inspection without any observations," Granules India said in a BSE filing.

Pharma firm Granules India today said its Gagillapur facility in Hyderabad has completed USFDA inspection without any observations.

"The company's Gagillapur facility located in Hyderabad, Telangana... has successfully completed US FDA inspection without any observations," Granules India said in a BSE filing.

"This facility manufactures finished dosages (FDs) and pharmaceutical formulation intermediates (PFIs)." The stock of Granules India was trading 2.29 per cent higher at Rs 122.75 on BSE.

Sections
Follow us on
Available On